Lupin Announces FDA Approval of SOLOSEC (Secnidazole)
Summary : SOLOSEC® demonstrated a 92.2% clinically and statistically significant cure rate for patients with trichomoniasis based on a landmark Phase 3…
Summary : SOLOSEC® demonstrated a 92.2% clinically and statistically significant cure rate for patients with trichomoniasis based on a landmark Phase 3…
Summary : Merck & Co Inc and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir…
SYNOPSIS US government contracts for approximately $1 billion (USD) are now in place to purchase Sotrovimab, further expanding access nationwide Sotrovimab, an…
Abstract: A new global agreement – the Glasgow Climate Pact – was reached at the COP26 summit. It aims to reduce the…
KEYPOINTS: The product is a generic version of the Lupin Atlantis Holdings, S A Corporation’s Antara capsules Fenofibrate Capsules (RLD: Antara Capsules)…
KEYPOINTS: The UK became the first country to approve Covid-19 antiviral pill, jointly developed by US-based Merck & Co Inc and Ridgeback…
A research project conducted by the Rajiv Gandhi Centre for Biotechnology (RGCB) here has found that the berry-bearing black nightshade shrub could…